Back
 AJAC  Vol.4 No.10 B , October 2013
Determination of Calcineurin Inhibitors in Dried Blood Spots from Kidney Transplant Recipients
Abstract: Background: Determination of cyclosporine A (CsA) and tacrolimus (Tac) in dried blood spots (DBS) could enable drug monitoring in transplanted patients without the necessity of having to take venous blood samples. Therefore, we have developed a method for quantitative determination of calcineurin inhibitors (CNI) by liquid-chromatography-tandem mass spectrometry (LCMS). Methods: In a study with 68 kidney transplant recipients (KTR, 34 CsA, 34 Tac), we tested the clinical application of LCMS monitoring in DBS in comparison to LCMS in whole blood. Results: The measuring range is proven for 27.33 to 1345 ng/ml for CsA and for 1.63 to 39.7 ng/ml for Tac. The requirements for clinical chemical analyses for precision and accuracy are complied with. Stability is documented for a period of 14 days. The study showed the following deviations from LCMS in whole blood for determination of CsA and Tac in DBS after introducing a correction factor by the haematocrit (Hct) value (CsA trough level: mean = 4.7%, ±1.96 standard deviation (SD) -52.1% to 61.4%, N = 96; CsA peak level: mean = 7.3%, ±1.96 SD -39.7% to 54.4%, N = 95; Tac trough level: mean = -0.5%, ±1.96 SD -76.4% to 75.3%, N = 88; Tac peak level: mean = 3.9%, ±1.96 SD -80.1% to 88.7%, N = 92). Conclusions: Our data show comparable results with the reference method by means of LCMS in whole blood. Therefore, DBS of KTR for determination of CNI levels could be transported on filter cards by mail to the respective laboratory resistant to breakage and the hazard of infection.
Cite this paper: L. Wilhelm, M. Nitschke, M. Meier, R. Vonthein and J. Kramer, "Determination of Calcineurin Inhibitors in Dried Blood Spots from Kidney Transplant Recipients," American Journal of Analytical Chemistry, Vol. 4 No. 10, 2013, pp. 27-35. doi: 10.4236/ajac.2013.410A2004.
References

[1]   S. F. Yu, L. H. Wu and S. S. Zheng, “Genetic Factors for Individual Administration of Immunosuppressants in Organ Transplantation,” Hepatobiliary & Pancreatic Diseases International, Vol. 5, No. 3, 2006, pp. 337-344.

[2]   A. L. Taylor, C. J. Watson and J. A. Bradley, “Immunosuppressive Agents in Solid Organ Transplantation: Mechanisms of Action and Therapeutic Efficacy,” Critical Reviews in Oncology/Hematology, Vol. 56, No. 1, 2005, pp. 23-46.
http://dx.doi.org/10.1016/j.critrevonc.2005.03.012

[3]   J. E. Murray, A. G. Sheil, R. Moseley, P. Knight, J. D. McGavic and G. J. Dammin, “Analysis of Mechanism of Immunosuppressive Drugs in Renal Homotransplantation,” Annals of Surgery, Vol. 160, No. 3, 1964, pp. 449-473.
http://dx.doi.org/10.1097/00000658-196409000-00009

[4]   F. Akhlaghi and A. K. Trull, “Distribution of Cyclosporin in Organ Transplant Recipients,” Clinical Pharmacokinetics, Vol. 41, No. 9, 2002, pp. 615-37.
http://dx.doi.org/10.2165/00003088-200241090-00001

[5]   T. E. Starzl, S. Todo, J. Fung, A. J. Demetris, R. Venkataramman and A. Jain, “FK 506 for Liver, Kidney, and Pancreas Transplantation,” Lancet, Vol. 2, No. 8670, 1989, pp. 1000-1004.
http://dx.doi.org/10.1016/S0140-6736(89)91014-3

[6]   M. Fireman, A. F. DiMartini, S. C. Armstrong and K. L. Cozza, “Immunosuppressants,” Psychosomatics, Vol. 45, No. 4, 2004, pp. 354-360.
http://dx.doi.org/10.1176/appi.psy.45.4.354

[7]   P. M. Shaw, T. S. Barnes, D. Cameron, J. Engeset, W. T. Melvin, G. Omar, J. C. Petrie, W. R. Rush, C. P. Snyder and P. H. Whiting, “Purification and Characterization of an Anticonvulsant-Induced Human Cytochrome P-450 Catalysing Cyclosporin Metabolism,” Biochemical Journal, Vol. 263, No. 3, 1989, pp. 653-663.

[8]   L. M. Shaw, “Advances in Cyclosporine Pharmacology, Measurement, and Therapeutic Monitoring,” Clinical Chemistry, Vol. 35, No. 7, 1989, pp. 1299-308.

[9]   M. Naesens, D. R. Kuypers and M. Sarwal, “Calcineurin Inhibitor Nephrotoxicity,” Clinical Journal of the American Society of Nephrology, Vol. 4, No. 2, 2009, pp. 481-508.

[10]   B. L. Kasiske, M. G. Zeier, J. R. Chapman, J. C. Craig, H. Ekberg, C. A. Garvey, M. D. Green, V. Jha, M. A, Josephson, B. A. Kiberd, H. A. Kreis, R. A. McDonald, J. M. Newmann, G. T. Obrador, F. G. Vincenti, M. Cheung, A. Earley, G. Raman, S. Abariga, M. Wagner and E. M. Balk, “KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients: A Summary,” Kidney International, Vol. 77, No. 4, 2009, pp. 299-311.

[11]   K. M. Rentsch, “Monitoring of Immunosuppressant Drug,” Therapeutische Umschau, Vol. 65, No. 9, 2008, pp. 545-550.
http://dx.doi.org/10.1024/0040-5930.65.9.545

[12]   Abbott-Laboratories, “Architect System—Cyclosporine,” 2010.

[13]   Abbott-Laboratories, “Architect System—Tacrolimus,” 2010.

[14]   U. Ceglarek, J. Lembcke, G. M. Fiedler, M. Werner, H. Witzigmann, J. P. Hauss and J. Thiery, “Rapid Simultaneous Quantification of Immunosuppressants in Transplant Patients by Turbulent Flow Chromatography Combined with Tandem Mass Spectrometry,” Clinica Chimica Acta, Vol. 346, No. 2, 2004, pp. 181-190
http://dx.doi.org/10.1016/j.cccn.2004.03.017

[15]   P. D. Acott, “Home Fingerprick Sampling for Immunosuppressant Drug Monitoring in Pediatric Renal Transplant Patients,” Clinical Journal of the American Society of Nephrology, Vol. 2, No. 6, 2006, pp. 304-305.

[16]   B. G. Keevil, J. Fildes, A. Baynes and N. Yonan, “Liquid Chromatography-Mass Spectrometry Measurement of Tacrolimus in Finger-Prick Samples Compared with Venous Whole Blood Samples,” Annals of Clinical Biochemistry, Vol. 46, No. 2, 2009, pp. 144-145.
http://dx.doi.org/10.1258/acb.2008.008147

[17]   B. G. Keevil, D. P. Tierney, D. P. Cooper, M. R. Morris, A. Machaal, N. Yonan, “Simultaneous and Rapid Analysis of Cyclosporin A and Creatinine in Finger Prick Blood Samples Using Liquid Chromatography Tandem Mass Spectrometry and Its Application in C2 Monitoring,” Therapeutic Drug Monitoring, Vol. 24, No. 6, 2002, pp. 757-767.
http://dx.doi.org/10.1097/00007691-200212000-00013

[18]   A. B. Leichtle, U. Ceglarek, H. Witzigmann, G. Gabel, J. Thiery and G. M. Fiedler, “Potential of Dried Blood SelfSampling for Cyclosporine c(2) Monitoring in Transplant Outpatients,” Journal of Transplantation, Vol. 2010, 2010, Article ID. 201918.

[19]   G. Merton, K. Jones, M. Lee, A. Johnston, D. W. Holt, “Accuracy of Cyclosporin Measurements Made in Capillary Blood Samples Obtained by Skin Puncture,” Therapeutic Drug Monitoring, Vol. 22, No. 5, 2000, pp. 594-598.
http://dx.doi.org/10.1097/00007691-200010000-00015

[20]   M. D. Pettersen, D. J. Driscoll, T. P. Moyer, J. A. Dearani and C. G. McGregor, “Measurement of Blood Serum Cyclosporine Levels Using Capillary “Fingerstick” Sampling: A Validation Study,” Transplant International, Vol. 12, No. 6, 1999, pp. 429-432.

[21]   R. J. Profumo, T. M. Foy and R. E. Kane, “Correlation between Venous and Capillary Blood Samples for Cyclosporine Monitoring in Pediatric Liver Transplant Patients,” Clinical Transplantation, Vol. 9, No. 5, 1995, pp. 424-426.

[22]   N. J. Webb, M. G. Coulthard, R. S. Trompeter, M. M. Fitzpatrick, S. Stephens, J. Dudley, H. Maxwell, S. Waller, G. C. Smith, A. R. Watson, D. A. Hughes, B. G. Keevil and J. S. Ellis, “Correlation between Fingerprick and Venous Ciclosporin Levels: Association with Gingival Overgrowth and Hypertrichosis,” Pediatric Nephrology, Vol. 22, No. 12, 2007, pp. 2111-2118.
http://dx.doi.org/10.1007/s00467-007-0586-z

[23]   N. J. Webb, D. Roberts, R. Preziosi and B. G. Keevil, “Fingerprick Blood Samples Can Be Used to Accurately Measure Tacrolimus Levels by Tandem Mass Spectrometry,” Pediatric Transplantation, Vol. 9, No. 6, 2005, pp. 729-733.
http://dx.doi.org/10.1111/j.1399-3046.2005.00367.x

[24]   N. Yonan, R. Martyszczuk, A. Machaal, A. Baynes and B. G. Keevil, “Monitoring of Cyclosporine Levels in Transplant Recipients Using Self-Administered Fingerprick Sampling,” Clinical Transplantation, Vol. 20, No. 2, 2006, pp. 221-225.
http://dx.doi.org/10.1111/j.1399-0012.2005.00472.x

[25]   C. Y. Cheung, J. van der Heijden, K. Hoogtanders, M. Christiaans, Y. L. Liu, Y. H. Chan, K. S. Choi, A. van de Plas, C. C. Shek, K. F. Chau, C. S. Li, J. van Hooff and L. Stolk, “Dried Blood Spot Measurement: Application in Tacrolimus Monitoring Using Limited Sampling Strategy and Abbreviated AUC Estimation,” Transplant International, Vol. 21, No. 2, 2008, pp. 140-145.

[26]   K. Hoogtanders, J. van der Heijden, M. Christiaans, P. Edelbroek, J. P. van Hooff and L. M. Stolk, “Therapeutic Drug Monitoring of Tacrolimus with the Dried Blood Spot Method,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 44, No. 3, 2007, pp. 658-664.
http://dx.doi.org/10.1016/j.jpba.2006.11.023

[27]   K. Hoogtanders, J. van der Heijden, M. Christiaans, A. van de Plas, J. van Hooff and L. Stolk, “Dried Blood Spot Measurement of Tacrolimus Is Promising for Patient Monitoring,” Transplantation, Vol. 83, No. 2, 2007, pp. 237-238.
http://dx.doi.org/10.1097/01.tp.0000250730.30715.63

[28]   B. G. Keevil, “The Analysis of Dried Blood Spot Samples Using Liquid Chromatography Tandem Mass Spectrometry,” Clinical Biochemistry, Vol. 44, No. 1, 2011, pp. 110-108.
http://dx.doi.org/10.1016/j.clinbiochem.2010.06.014

[29]   D. Lampe, D. Scholz, H. J. Prumke, W. Blank and H. Huller, “Capillary Blood, Dried on Filter Paper, as Sample for Monitoring Cyclosporin A Concentrations,” Clinical Chemistry, Vol. 33, No. 9, 1987, pp. 1643-1644.

[30]   A. J. Wilhelm, J. C. den Burger, R. M. Vos, A. Chahbouni and A. Sinjewel, “Analysis of Cyclosporin A in Dried Blood Spots Using Liquid Chromatography Tandem Mass Spectrometry,” Journal of Chromatography B, Vol. 877, No. 14-15, 2009, pp. 1595-1598.
http://dx.doi.org/10.1016/j.jchromb.2009.03.024

[31]   E. Hinchliffe, J. E. Adaway and B. G. Keevil, “Simultaneous Measurement of Cyclosporin A and Tacrolimus from Dried Blood Spots by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry,” Journal of Chromatography B, Vol. 883-884, 2012, pp. 102-107. http://dx.doi.org/10.1016/j.jchromb.2011.05.016

[32]   A. Mendonza, R. Gohh and F. Akhlaghi, “Determination of Cyclosporine in Saliva Using Liquid Chromatography-Tandem Mass Spectrometry,” Therapeutic Drug Monitoring, Vol. 26, No. 5, 2004, pp. 569-575.
http://dx.doi.org/10.1097/00007691-200410000-00016

[33]   W. Funk, V. Dammann and G. Donnevert, “Qualitatsicherung in der Analytischen Chemie,” Wiley-VCH Verlag GmbH &Co.KgaA, Weinheim, 2005.

[34]   W. Funk, D.-I. Vera Dammann, D.-I. Gerhild Donnevert, “Qualitatssicherung in der Analytischen Chemie: Anwendungen in der Umwelt-, Lebensmittelund Werkstoffanalytik, Biotechnologie und Medizintechnik,” 1994.
http://dx.doi.org/10.1002/9783527624508

[35]   F. T. Peters, L. D. Paul, F. Muβhoff, B. Aebi, V. Auwarter, T. Kraemer and G. Skopp, “Anforderungen an die Validierung von Analysenmethoden,” ToxChem und KrimTech, Vol. 76, No. 3, 2009, pp. 185-209.

[36]   DIN 53804, “Teil 1: Statistische Auswertung,” 1990.

[37]   S. Capiau, V. V. Stove, W. E. Lambert and C. P. Stove, “Prediction of the Hematocrit of Dried Blood Spots via Potassium measurement on a Routine Clinical Chemistry Analyzer,” Analytical Chemistry, Vol. 85, No. 1, 2013, pp. 404-410. http://dx.doi.org/10.1021/ac303014b

 
 
Top